Get the Stockscreener App
2.78
1.42%
-0.04
Exicure Inc stock is traded at $2.78, with a volume of 24,924.
It is down -1.42% in the last 24 hours and down -14.20% over the past month.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
See More
Previous Close:
$2.82
Open:
$2.92
24h Volume:
24,924
Relative Volume:
1.40
Market Cap:
$17.72M
Revenue:
$500.00K
Net Income/Loss:
$-9.78M
P/E Ratio:
-1.803
EPS:
-1.5419
Net Cash Flow:
$-8.10M
1W Performance:
-4.79%
1M Performance:
-14.20%
6M Performance:
-56.22%
1Y Performance:
-69.08%
1-Day Range:
$2.71
$3.05
1-Week Range:
$2.70
$3.10
52-Week Range:
$2.62
$9.50
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR vs MOBBW, GOODO, SHMD, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.51 | 3.33B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.16 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.38 | 342.89M | 52.15M | -21.46M | 0 | -0.4675 |
PSNYW
Polestar Automotive Holding Uk
|
2.85 | 263.64M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.16 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
Exicure receives Nasdaq notice for falling below $2.5M equity requirement, plans to regain compliance. - Pluang
Exicure receives Nasdaq notice for equity deficiency - Investing.com
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement - The Manila Times
Exicure receives Nasdaq notice for equity deficiency By Investing.com - Investing.com Canada
Exicure Inc stock (US30205M1027): biotech penny stock seeks direction after strategic shifts - AD HOC NEWS
XCUR Technical Analysis | Trend, Signals & Chart Patterns | EXICURE INC (NASDAQ:XCUR) - ChartMill
Exicure Regains Nasdaq Compliance After Late Quarterly Filing - The Globe and Mail
Exicure Announces Receipt Of Nasdaq Delinquency Notice And Filing Of Form 10-Q - TradingView
Exicure receives Nasdaq notice for delayed quarterly filing By Investing.com - Investing.com South Africa
Exicure receives Nasdaq notice for delayed quarterly filing - Investing.com
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - The Manila Times
Exicure faces Nasdaq noncompliance over late 10-Q, then files report - Stock Titan
Exicure receives Nasdaq notice for late 10-Q, files report and says compliance restored - TradingView
Exicure (XCUR) addresses Nasdaq delinquency after delayed Q1 2026 10-Q filing - Stock Titan
Exicure resolves Nasdaq filing delay, regains compliance after late 10-Q submission - Pluang
Exicure, Inc. Q1 2026 Financials: Strategic Alternatives, Going Concern Doubts, and Zero Revenue Reported - Minichart
XCUR Q2 2022 Earnings: EPS Misses Estimates Amid Operational ChallengesProfit Margin Analysis - The Legal Advocate
Exicure Q2 2022 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues DevelopmentEarnings Outlook Update - The Legal Advocate
Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Exicure (NASDAQ: XCUR) posts Q1 2026 loss and flags going concern, Nasdaq risks - Stock Titan
Exicure Deadline Alert - TMX Newsfile
XCUR Q2 2022 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No RevenueFinancial Health Score - newsline.com
Exicure Inc. (XCUR) Q2 2022 Earnings: Wider-than-Expected Loss, No Revenue, Shares Edge Higher - The Legal Advocate
Exicure (XCUR) Q2 2022 Earnings: Wider-Than-Expected Loss Fails to Deter InvestorsStock Idea Network - Newser
Exicure Inc. (XCUR) Slips 3.6% as Shares Test Support Near $2.53Stock Idea Hub - Newser
XCUR Q2 2022 Earnings: Wider-than-Expected Loss Highlights Challenges for Pre-Revenue Biotech - Newser
Exicure Inc stock (US30205M1027): micro-cap biotech restructures after Nasdaq delisting - AD HOC NEWS
Exicure delays quarterly filing, trims quarterly loss - TipRanks
Exicure (XCUR) delays Q1 2026 10-Q; prelim net loss $1.83M - Stock Titan
Exicure stock (US30205M1027): Filing highlights ongoing biotech focus - AD HOC NEWS
TradingKey - TradingKey
XCUR (Exicure) shares decline 3% after EPS miss of 35.6%, raising concerns over biotech's cash burn and growth prospects.Trending Social Stocks - Newser
The biggest catalyst for Exicure (XCUR) nobody is watching (-1.82%) 2026-05-11Open Trading Community - Newser
Number of shareholders of Exicure, Inc. – SWB:2H0 - TradingView
Exicure Shareholder Alert - TMX Newsfile
What Exicure (XCUR) does that its rivals cannot (+2.12%) 2026-05-08Investment Community Signals - newser.com
The real value proposition of Exicure (XCUR) stock (-0.29%) 2026-05-06Value Ideas - Newser
XCUR Exicure shares drop 4.67% after Q2 2022 loss per share comes in far wider than analyst estimates.Social Buzz Stocks - Newser
XCUR Exicure Inc. posts wider than projected Q1 2022 loss while its shares climb on positive investor sentiment. - UBND thành phố Hải Phòng
Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies - Quiver Quantitative
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - The Globe and Mail
Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100) - marketscreener.com
New Exicure pact targets Burixafor combos for sickle cell, leukemia - Stock Titan
Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100) - marketscreener.com
Exicure (XCUR) Stock: Next Week (Touches Low) 2026-04-20Crowd Risk Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Exicure Inc (FRA:2H0) Stock Price, Trades & News - GuruFocus
What do insiders think about Exicure (XCUR) Stock | Price at $3.81, Up 0.87%Trend Following Picks - The Legal Advocate
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):